Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

15
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

16
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
Structure of Cardiac Muscles01:13

Structure of Cardiac Muscles

12.9K
Cardiac muscle, or myocardium, is a specialized type of muscle found exclusively in the heart. Its unique structural and functional characteristics enable the heart to perform its vital role of pumping blood throughout the body continuously and rhythmically. The cardiac muscle cells, or cardiomyocytes, possess an endomysium and perimysium but do not have an epimysium.
Compared to skeletal muscles, cardiac muscle cells are small and mostly have a single nucleus. Additionally, they are usually...
12.9K
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

15
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
15
Overview of Secretory Vesicles01:33

Overview of Secretory Vesicles

8.6K
Secretory vesicles, also known as dense core vesicles (DCVs), are membrane-bound vesicles that transport secretory proteins, such as hormones or neurotransmitters. Regulated secretory vesicles transport proteins from the trans-Golgi network to the exterior of the cell. Proteins present in regulated secretory vesicles are required to be rapidly exocytosed in large amounts upon a specific stimulus.
Various proteins regulate the aggregation of molecules inside the secretory vesicles. Chromogranins...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chromosome-Level Genome Assembly of the Sea Urchin Glyptocidaris crenularis and Sex Chromosome Identification.

Biochemical genetics·2026
Same author

Large-Scale Genomic Analysis of Stripe Rust Resistance in Chinese Wheat Germplasm Using Multi-Environment Trial Data.

Plant disease·2026
Same author

Targeting THOC2-Mediated mRNA Export Induces PARP Inhibitor Vulnerability in DNA Repair-Competent Hepatocellular Carcinoma.

International journal of biological sciences·2026
Same author

Sex-Specific Outcomes and Treatment Responses in Elderly Patients With Heart Failure With Preserved Ejection Fraction: A Comprehensive Single-Center Retrospective Study.

Journal of the American Heart Association·2026
Same author

Comparative Prognostic Assessment of EKFC Equations for Mortality Prediction: A Population-based Cohort Study.

Cardiorenal medicine·2026
Same author

Exercise-induced FNDC5/irisin promote stress resilence in mice by targeting astrocytic GLT1 in the amygdala.

Brain, behavior, and immunity·2026

Related Experiment Video

Updated: Jul 18, 2025

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.1K

Extracellular Vesicles and Pathological Cardiac Hypertrophy.

Rongrong Gao1, Xinli Li1

  • 1Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Advances in Experimental Medicine and Biology
|August 21, 2023
PubMed
Summary

Extracellular vesicles (EVs) play a key role in cardiac hypertrophy, a risk factor for cardiovascular diseases. These EVs show promise as diagnostic biomarkers and therapeutic targets for heart conditions.

Keywords:
BiomarkersExosomesExtracellular vesiclesPathological cardiac hypertrophyTherapeutic agentsmicroRNAs

More Related Videos

Magnetic Adjustment of Afterload in Engineered Heart Tissues
09:40

Magnetic Adjustment of Afterload in Engineered Heart Tissues

Published on: May 5, 2020

5.9K
An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

5.8K

Related Experiment Videos

Last Updated: Jul 18, 2025

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.1K
Magnetic Adjustment of Afterload in Engineered Heart Tissues
09:40

Magnetic Adjustment of Afterload in Engineered Heart Tissues

Published on: May 5, 2020

5.9K
An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

5.8K

Area of Science:

  • Cardiology
  • Molecular Biology
  • Cell Biology

Background:

  • Pathological cardiac hypertrophy is a significant risk factor for cardiovascular diseases (CVDs).
  • Intercellular communication via extracellular vesicles (EVs) is increasingly recognized in cardiac hypertrophy progression.
  • EVs mediate communication between cardiomyocytes and noncardiomyocytes, influencing cardiac remodeling.

Purpose of the Study:

  • To summarize current knowledge on EVs in pathological cardiac hypertrophy.
  • To explore the potential of EVs as diagnostic and prognostic biomarkers.
  • To evaluate EVs as therapeutic targets for myocardial hypertrophy.

Main Methods:

  • Review of existing literature on EVs in cardiac hypertrophy.
  • Analysis of autocrine and paracrine functions of EVs.
  • Assessment of EV characteristics for biomarker and therapeutic applications.

Main Results:

  • EVs facilitate intercellular communication, impacting cardiac hypertrophy.
  • EVs contain bioactive molecules (nucleic acids, proteins) involved in cardiac remodeling.
  • EVs exhibit potential as biomarkers and therapeutic agents due to biocompatibility and low immunogenicity.

Conclusions:

  • EVs are crucial in the complex mechanisms of pathological cardiac hypertrophy.
  • EVs represent a promising avenue for novel diagnostic and therapeutic strategies in cardiovascular diseases.